Medunik Canada signs an exclusive agreement with HRA pharma for commercialization of Lysodren® (mitotane) in Canada, for the treatment of inoperable adrenal cortical carcinomas

BLAINVILLE, QC, Jan. 16, 2019 /CNW Telbec/ - Medunik Canada, a company dedicated to improving the health and quality of life of Canadians living with rare diseases, is proud to announce the signing of a licensing and supply agreement with HRA Pharma. The agreement grants Medunik Canada exclusive commercial rights in Canada for Lysodren®, indicated for the treatment of inoperable functional and non-functional adrenal cortical carcinoma.  

"We are particularly proud to add Lysodren® to Medunik Canada's portfolio of specialty products and treatments for orphan diseases. This addition is our first foray into the field of oncology and heralds great things in the near future, as we pursue our mission to support Canadian patients. In addition, with the launch of Lysodren®, we are embarking on a partnership with HRA Pharma, a French company that is a leader in women's health and endocrinology," affirmed Dany Hallé, Vice President, Commercial Affairs, Medunik Canada.

Adrenocortical cortical carcinoma (ACC)
Adrenal cortical carcinoma (ACC) is a rare disease. It is caused by a cancerous proliferation in the adrenal cortex, which is the outer layer of the adrenal glands. They play an important role in the endocrine system.

Lysodren® is used to treat people with advanced adrenal cortical carcinoma. 

Indication
Lysodren ® (mitotane) is only indicated for the treatment of inoperable functional and non-functional adrenal cortical carcinomas.

Contraindications
Lysodren® is contraindicated in patients with known hypersensitivity to mitotane or any other ingredient in the product.

Cautionary statement
Lysodren® should be administered under the supervision of a physician experienced in the administration of antineoplastic chemotherapeutic agents.

For more information about Lysodren®, please refer to the Product Monograph.

About Medunik Canada

Founded in 2009, Medunik Canada, a subsidiary of the Boivin Pharmaceutical Group, is dedicated to providing Canadians with rare diseases with access to orphan drugs by establishing strategic partnerships with international companies to market their products in Canada.

Through the acquisition of product licenses from its partners, Medunik Canada offers turnkey services, including medical advisors, and ensures the smooth operation of approval and market access processes as well as the marketing of orphan drugs. For more information, please visit our website at www.medunikcanada.com.

About HRA Pharma
HRA Pharma is a fast growing, innovative pharmaceutical company empowering people throughout the world to improve their lives by developing accessible, value added, healthcare solutions. The company has a fully-dedicated Endocrinology & Rare Diseases division, whose mission is to make meaningful health solutions broadly accessible to rare disease patients with a portfolio of products (medicines) that address Cushing's syndrome (CS) and Adrenal Cortical Carcinoma (ACC).

For more information, please visit www.hra-pharma.com.

SOURCE Médunik Canada

Media inquiries: Alida Alepian, Senior Advisor, Capital-Image, [phone], ext. 239, [e-mail]